Stockreport

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Cidara Therapeutics, Inc.  (CDTX) 
Last cidara therapeutics, inc. earnings: 3/4 05:55 am Check Earnings Report
US:NASDAQ Investor Relations: ir.cidara.com
PDF Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment [Read more]